Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats

References

• Ansari JA, Bhandari U, Haque SE, Pillai KK. (2012). Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats. Toxicol Mech Methods 22:67–73.
   PubMed Web of Science ®Google Scholar
• Barbosa-Sicard E, Markovic M, Honeck H, Christ B, Muller DN, Schunck WH. (2005). Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem Biophys Res Commun 329:1275–1281.
   PubMed Web of Science ®Google Scholar
• Daniel WA, Haduch A, Syrek M, Boksa J. (2006). Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment. Eur Neuropsychopharmacol 16:580–587.
   PubMed Web of Science ®Google Scholar
• Delsing DJ, Post SM, Groenendijk M, Solaas K, van der Boom H, van Duyvenvoorde W, de Wit EC, Bloks VW, Kuipers F, Havekes LM, Princen HM. (2005). Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice. J Cardiovasc Pharmacol 45:53–60.
   PubMedGoogle Scholar
• Fassini PG, Noda RW, Ferreira ES, Silva MA, Neves VA, Demonte A. (2011). Soybean glycinin improves HDL-C and suppresses the effects of rosuvastatin on hypercholesterolemic rats. Lipids Health Dis 10:165.
   PubMed Web of Science ®Google Scholar
• Finsterer J, Stöllberger C. (2005). Myalgia, hyper-CK-aemia, and hypocoagulability in a patient under rosuvastatin and warfarin. Eur J Neurol 12:660.
   PubMedGoogle Scholar
• Galani V, Vyas M. (2010). In vivo and In vitro drug interactions study of Glimepride with Atorvastatin and Rosuvastatin. J Young Pharm 2:196–200.
   PubMedGoogle Scholar
• Gallelli L, Ferraro M, Spagnuolo V, Rende P, Mauro GF, De Sarro G. (2009). Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation. Drug Metabol Drug Interact 24:83–87.
   PubMedGoogle Scholar
• Guengerich FP, Dannan GA, Wright ST, Martin MV, Kaminsky LS. (1982). Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. Biochemistry 21:6019–6030.
   PubMed Web of Science ®Google Scholar
• Havel RJ, Eder HA, Bragdon JH. (1955). The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345–1353.
   PubMed Web of Science ®Google Scholar
• Ishizuka M, Okajima F, Tanikawa T, Min H, Tanaka KD, Sakamoto KQ, Fujita S. (2007). Elevated warfarin metabolism in warfarin-resistant roof rats (Rattus rattus) in Tokyo. Drug Metab Dispos 35:62–66.
   PubMed Web of Science ®Google Scholar
• Jindal D, Tandon M, Sharma S, Pillai KK. (2005). Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects. Eur J Clin Pharmacol 61:621–625.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Elisaf MS. (2010). Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 10:11–28.
   PubMed Web of Science ®Google Scholar
• Lake BG. Preparation and characterization of microsomal fractions for studies on xenobiotic metabolism. (1990). In: Snell EK, Mullock B. Biochemical toxicology and practical approach. Oxford-Washington DC: IRL Press, 183.
   Google Scholar
• Locatelli I, Kmetec V, Mrhar A, Grabnar I. (2005). Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B Analyt Technol Biomed Life Sci 818:191–198.
   PubMed Web of Science ®Google Scholar
• McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M. (2001). Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87:28B–32B.
   PubMed Web of Science ®Google Scholar
• Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF. (2009). New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab 10:1075–1126.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ. (2010). Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 11:323–332.
   PubMed Web of Science ®Google Scholar
• Nezasa K, Takao A, Kimura K, Takaichi M, Inazawa K, Koike M. (2002). Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. Xenobiotica 32:715–727.
   PubMed Web of Science ®Google Scholar
• Orolin J, Vecera R, Markova I, Zacharova A, Anzenbacher P. (2009). Differences in hepatic expression of genes involved in lipid homeostasis between hereditary hypertriglyceridemic rats and healthy Wistar rats and in their response to dietary cholesterol. Food Chem Toxicol 47:2624–2630.
   PubMed Web of Science ®Google Scholar
• Pennisi G, Vacante M, Russo C, Malaguarnera M. (2010). Rhabdomyolysis induced by rosuvastatin and sildenafil. South Med J 103:1052–1054.
   PubMedGoogle Scholar
• Reisin E, Ebenezer PJ, Liao J, Lee BS, Larroque M, Hu X, Aguilar EA, Morse SA, Francis J. (2009). Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet. Am J Med Sci 338:301–309.
   PubMed Web of Science ®Google Scholar
• Rubba P, Marotta G, Gentile M. (2009). Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vasc Health Risk Manag 5:343–352.
   PubMedGoogle Scholar
• Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW. (2005). Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 45:927–934.
   PubMed Web of Science ®Google Scholar
• Sugatani J, Sadamitsu S, Kurosawa M, Ikushiro S, Sakaki T, Ikari A, Miwa M. (2010). Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats. Drug Metab Dispos 38:1655–1664.
   PubMedGoogle Scholar
• Vecera R, Skottová N, Vána P, Kazdová L, Chmela Z, Svagera Z, Walterá D, Ulrichová J, Simánek V. (2003). Antioxidant status, lipoprotein profile and liver lipids in rats fed on high-cholesterol diet containing currant oil rich in n-3 and n-6 polyunsaturated fatty acids. Physiol Res 52:177–187.
   PubMedGoogle Scholar
• Vecera R, Zacharová A, Orolin J, Strojil J, Skottová N, Anzenbacher P. (2011). Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Biopharm Drug Dispos 32:482–487.
   PubMed Web of Science ®Google Scholar
• Wang H, Cheng JD, Montgomery D, Cheng KC. (2009). Evaluation of the binding orientations of testosterone in the active site of homology models for CYP2C11 and CYP2C13. Biochem Pharmacol 78:406–413.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimada T. (1997). Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem Pharmacol 54:1195–1203.
   PubMed Web of Science ®Google Scholar
• Full Prescribing Information www.crestor.com. Accessed on 1 December 2011.
   Google Scholar